For Non-US Residents
Many people who display the most common symptoms of Parkinson's never experience anything worse. However, if the subtle symptoms shift, patients may notice things like:
• more tremor
• increased muscle stiffness
• noticeable slowness of movement
• difficulty swallowing and speaking
• sexual problems (in men)
In cases where these symptoms are present, the disease can be managed successfully for many, many years, especially with the help of prescription drugs.
The later stages
As PD progresses, symptoms may get more serious and include:
• problems maintaining balance
• periods of extreme confusion or hallucinations
• severe depression or withdrawal
PD happens most commonly to middle-aged and elderly people; only 10% of people with PD are under the age of 40. About a million Americans are believed to suffer from PD. Approximately 50,000 new cases are reported every year.
Emotional and non-motor symptoms
Not all symptoms of PD have to do with movement. People with Parkinson’s disease can also experience the following symptoms, whether or not they are experiencing movement (motor) difficulties:
• heart disease
• handwriting problems
• loss of sense of smell
• sleep disturbances or nightmares
• loss of energy
In fact, many people say that in the long run, they suffer more from the effects of these symptoms than from movement-related symptoms. There are many ways to combat emotional and non-motor symptoms. Start by asking your doctor, then try looking into the resources section of this site.
TASMAR SHOULD NOT BE USED BY PATIENTS UNTIL THERE HAS BEEN A COMPLETE DISCUSSION OF THE RISKS AND THE PATIENT HAS PROVIDED WRITTEN INFORMED CONSENT (SEE PATIENT ACKNOWLEDGEMENT FORM).
WARNING: Because of the risk of potentially fatal, acute fulminant liver failure, TASMAR (tolcapone) should ordinarily be used in patients with Parkinson's disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies (see INDICATIONS and DOSAGE AND ADMINISTRATION sections).
TASMAR therapy should not be initiated if the patient exhibits clinical evidence of liver disease or two SGPT/ALT or SGOT/AST values greater than the upper limit of normal. Patients with severe dyskinesia or dystonia should be treated with caution (see PRECAUTIONS: Rhabdomyolysis).
Laboratory Tests: Although a program of frequent laboratory monitoring for evidence of hepatocellular injury is deemed essential, it is not clear that periodic monitoring of liver enzymes will prevent the occurrence of fulminant liver failure. However, it is generally believed that early detection of drug-induced hepatic injury along with immediate withdrawal of the suspect drug enhances the likelihood for recovery. Accordingly, the following liver monitoring program is recommended.
Please see accompanying complete prescribing information including BOXED warning.
TASMAR® is a registered trademark of Valeant Pharmaceuticals International